Posts by: Daniela Semedo

Daniela Semedo

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

February 25, 2016February 25, 2016

Study Finds Link Between Melanoma and Parkinson’s Disease, Researchers Say

News

Recent findings indicate there may be a link between Parkinson’s disease and melanoma, with family history and common genetic susceptibility as possible causes. The review is published in the journal Dermatologic Surgery ... Read more

February 16, 2016February 16, 2016

Many Stage 3 Melanoma Patients Won’t Benefit from High-dose Interferon Therapy, Study Finds

News

Final results of the Sunbelt Melanoma Trial indicate that most patients with stage III melanoma do not benefit from high-dose interferon treatment, largely because improved diagnostic techniques are now capable of detecting small amounts of ... Read more

February 9, 2016February 9, 2016

Rockland Immunochemicals Has New Melanoma Cell Lines Available for Research

News

Rockland Immunochemicals, Inc., announced the research availability of a new and diverse collection of more than 100 highly characterized human melanoma cell lines, made possible through a partnership between the company ... Read more

February 4, 2016February 4, 2016

Melanoma Rise Among Younger Women in US Associated with Indoor Tanning Use

News

University of Minnesota researchers have found that women under age 40 diagnosed with melanoma began indoor tanning at an earlier age and frequented the facilities more often than older women diagnosed with this malignancy. ... Read more

February 2, 2016February 2, 2016

Philogen Launches Phase 3 Melanoma Clinical Trial

News

Philogen S.p.A. of Siena, Italy, recently launched a pivotal clinical trial in patients with stage 3B/C melanoma, after promising results from its Phase 2 trial of a novel immunotherapeutic combination treatment. Patients with stage 3B/C ... Read more

December 10, 2015December 10, 2015

Metastatic Melanoma Immunotherapy Shows Promise in Mice Study

News

Memgen LLC, a company that develops cancer immunotherapies, presented positive preclinical data for its main immuno-oncology drug, ISF35, during the 30th annual meeting of the Society of Immunotherapy of Cancer (SITC), ... Read more

December 3, 2015December 3, 2015

Amgen Pressing Forward with Promising Melanoma Therapy

News

Amgen recently presented additional results from the company’s Phase 3 clinical trial of Imlygic (talimogene laherparepvec) as a monotherapy for the treatment of metastatic melanoma, as well as new results from its ongoing ... Read more

November 12, 2015November 12, 2015

Roche’s New Melanoma Drug, Cotellic, Gets FDA Approval

News

Roche recently announced that the U.S. Food and Drug Administration (FDA) approved Cotellic (cobimetinib) used in combination with Zelboraf (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive unresectable ... Read more

November 10, 2015November 12, 2015

New Metastatic Melanoma Treatment from Caladrius Shows Promise

News

Caladrius Biosciences, Inc., recently presented novel data at the 2015 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which took place in Baltimore, Maryland, Nov. 4-8, 2015. The clinical and ... Read more

November 5, 2015November 5, 2015

La Roche-Posay Promotes ‘SOS-Save Our Skin’ Program for 5th Year

News

La Roche-Posay, a global leader in ultraviolet (UV) protection, is continuing its work to increase public awareness of  skin cancer and prevention with its SOS – Save our Skin Campaign, now in ... Read more

October 15, 2015October 22, 2015

Dr. Alberto Pappo Interviewed About Pediatric Melanoma

News

Estimates indicate that each year in the United States, there are about 400 new diagnosis of melanoma among those younger than 19 years of age. According to the St. Jude Children’s ... Read more

August 10, 2015August 10, 2015

Pregnancy Does Not Influence Melanoma Prognosis

News

Results from a recent study published in the journal Dermatologic Surgery have shown that women who became pregnant after being diagnosed with melanoma did not experience a significantly worse clinical prognosis. ... Read more

July 31, 2015August 3, 2015

Castle Biosciences Receives Funding For Its DecisionDx-Melanoma Test

News

Castle Biosciences a company that develops and commercializes diagnostic and prognostic tests for cancers, recently announced it has raised $11.7 million to support the clinical adoption of the company’s DecisionDx-Melanoma ... Read more

July 29, 2015July 29, 2015

Novel Clinical Trial for BRAFV600-Advanced Melanoma Initiates Patient Recruitment

News

The ECOG-ACRIN Cancer Research Group recently announced it will begin patient enrolment in its Phase III cancer clinical trial that will compare two differently acting treatments that have previously shown to be effective ... Read more

July 24, 2015July 24, 2015

Georgetown University Medical Center Physician to Lead National Melanoma Clinical Trial

News

A renowned Georgetown University Medical Center physician will lead a national clinical trial involving new treatments for melanoma. The trial will compare two groups of drugs known for their efficacy ... Read more

June 19, 2015June 19, 2015

Moffitt Analysis Nivolumab Safety In Melanoma Patients

News

During the the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt ... Read more

June 17, 2015June 23, 2015

Modified Herpes Virus Increases Survival In Advanced Melanoma Patients

News

In a recent study published in the Journal of Clinical Oncology, University of Louisville researchers along with international colleagues found that patients with stage IIIb to IV melanoma treated with a modified ... Read more

June 12, 2015June 12, 2015

Provectus Begins Patient Enrolment for Phase 3 Trial of PV-10 for Melanoma

News

Provectus Biopharmaceuticals, Inc. a biopharmaceutical company specializing in developing oncology and dermatology therapies, recently announced that a new Phase 3 international FDA comparative clinical study of PV-10 in melanoma treatment has begun patient ... Read more

June 8, 2015June 9, 2015

Cancer Drug Increases Collagen in Melanoma

News

According to a recent report published in the Matrix Biology Journal titled “The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells”, collagen presence in the tumor microenvironment can be ... Read more

May 27, 2015

Melanoma Research Leads NYU Langone Presentations at ASCO 2015

News

During the 51st Annual Meeting of the American Society for Clinical Oncology (ASCO), NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center will present nearly 30 abstracts. ... Read more